T HE TREATMENT OF depression in patients with bipolar disorder has received surprisingly little re search attention. 1These patients are vulnerable to drug induced mania or rapid cycling.2 Whether particular an tidepressants are more effective in bipolar depression 3 or are less prone to induce mania or rapid cyclint has not been established. The safety and tolerability of the serotonin reuptake inhibitors (SRls) have made these drugs the standard first-line treatment for depression. Anecdotal reports have described drug-induced mania with the SRls,5 but they have not been well studied in bipolar depression. In this paper, I describe 11 patients who developed mania during treatment 'With SRIs.
Methods
Eleven patients who were treated at the Western Psychiatric Institute and Clinic for a manic episode that was precipitated by an SRr are described. Eight patients had been treated elsewhere as outpatients and were identified by the author after they were hos pitalized for severe drug-induced mania. Three were seen by the author during outpatient treatment. Pa tients' medical records were reviewed to obtain in formation about their-previous clinical and treatment history, family psychiatric history, clinical condition at the time of presentation, approximate time from the start of their antidepressant to the development of mania, and treatment outcome from their manic episode.
Results
Characteristics of the patients. are summarized in Table 1 . The patients were mostly young (mean age 33 years) women. Most had previous episodes of depres sion; only two patients Jm.d definite prior manic epi sodes. In five patients, past periods of possible hypo manic symptoms were retrospectively recognized by the patients themselves or their families. Only two had ever received pharmacotherapy before. All had signifi cant family histories of psychiatric illness. Eight pa tients became psychotic, and four were secluded for se vere agitation.
Only one patient (No.5) was taking a concurrent medication when the mania developed. She was re ceiving maintenance treatment with thiothixene, 4 mg/day, when she became depressed and was treated with fluoxetine. Severe mania developed within 2 weeks after she increased fluoxetine from 40 to 60 mg/day and simultaneously decreased thiothixene to 2 mg/day_ Patient No. 1 first developed mania within 2 weeks after receiving fluoxetine. She responded well to lithium, but was not compliant. Seven months later she was rehospitalized for major depression, and she developed a second manic episode within 1 week of taldng paroxetine. Patient No.2 initially developed hy
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~ pomania within 2 weeks afterfiuoxetine was increased from 20 to 40 mg/day. The drug was stopped, but was restarted at 20 mg/day 1 month later when she devel oped severe depression. She increased the dosage to 40 mg/dayand was then hospitalized within 2 weeks with severe mania. Patient No.3 initially developed severe mania during his first exposure to lluoxetine. He was stable on lithium and perphenazine until approxi mately 1 year later, when he was taken off these med ications. He was treated several months later with fiu oxetine alone for ml\ior depression and rehospitalized within 3 weeks for severe mania. Patient No. 7 had been treated previously with imipramine and tranyl cypromine for major depression, but she did not de velop mania, possibly because she was also taking lithium. These patients responded completely when the SRIs were stopped and appropriate antimanic treatment started.
Discussion
These 11 cases of SRI-induced mania were identified from a population of approximately 184 patients who were treated with various antidepressants, yielding an estimated incidence of about 6%. This finding cannot resolve the issue of whether certain antidepressants are more or less likely to precipitate mania, but it sug gests that the risk of SRI-induced mania is not trivial. Moreover, their episodes were generally quite severe. By contrast, a recent study found that treatment-emer gent mania tended to be less severe than spontaneous mania. 6 A recent study by Peet 7 examined pooled data from published and unpublished trials of various SRIs and tricyclic antidepressants (TeAs). Treatment-emergent mania was uncommon among unipolar depressives (less than 1%) and was substantially greater among bipolar depressives treated with TeAs (11.2%) com pared with SRIs (3.7%) and to placebo (4.2%). The au thor concluded that patients at risk for antidepressant induced mania should be treated with SRIs rather than TeAs, but this study deserves closer scrutiny.
First, the rate of mania among the unipolar depres sives 1 tends to increase linearly from the placebo (0.21%) to the TeA (0.52%) and to the SRI (0.72%) groups. The rates are significantly greater for active drug compared with placebo, but the statistical signifi cance of the difference between the TeA and SRI groups is not reported. Although the difference may not be clinically meaningful, this trend hints at a possible heightened sensitivity to SRI-induced mania, albeit less so in unipolar than in bipolar patients. Fluoxetine8-10 and monoamine oxidase inhibitors:}' 1I may be more ef fective than TeAs in bipolar depression. Also, fluvox amine was somewhat more effective in bipolar than in unipolar depression, 12 and clomipramine had a slightly greater antidepressant effect than maprotiline in bipo lar depression,13 although both studies are limited by the small number of patients. The superior efficacy of these antidepressants in bipolar depression may be due to their more potent serotonergic effects. a , 12 Interest ingly, serotonin precursors (Le., tryptophan) may have a greater antidepressant effect in bipolar than in unipo lar patients. 1 4-16 These findings suggest that bipolar pa tients are more sensitive to the effects of serotonergic drugs and are at greater risk for SRI-induced mania.
Second, Peet's study1 does not include infonnation about concurrent antimanic drug use. Compared with the SRIs, TCAs have been used clinically for a much longer time, and there has been increasing concern about the adverse effects of TCAs in bipolar patients. 2 Thus, bipolar patients treated with the recently avail able SRIs may be more likely to receive concurrent an timanic treatment because of the historical experience of TCA-induced mania or rapid cycling, which would bias the rate of treatment-emergent mania.
Finally, this study1 does not distinguish between bi polar I and n subtypes. 1 A different pro portion of bipolar subtypes could therefore bias the rate of drug-induced mania.
The problems associated with TCAs have been recog nized only gradually and only after many decades of clin icaluse.2.19 By contrast, the SRIs are believed to be "safer," but there has not been suflicient clinical experience to support this notion. Claims about the superior safety of the SRIs, therefore, must be critically evaluated Hypo mania is notoriously underrecogrrized, but may presage more severe manias.
2il Because patients are more likely to seek treatment when they are depressed rather than hy pomanic, a careful assessment of previous mood symp toms and family history is imperative before starting an antidepressant The SRLs now enjoy widespread use, es pecially by nonpsychiatric physicians, and many de pressed patients seek treatment in nonpsychiatric set tings. 21 Hence, many depressed patients may not be adequately evaluated and may be at risk for SRI-induced mania. Additional research is needed comparing the rela tive risk of treatment-emergent mania among different antidepressants and also in different bipolar subtypes, while controlling for concurrent antimanic drug use.
